The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Open accessAbstract
Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer (BC). Unfortunately, the resistance of BC to PTX treatment is a great obstacle in clinical applications and one of the major causes of death associated with treatment failure. Factors contributing to PTX resistance, such as ABC transporters, microRNAs (miRNAs), or mutations in certain genes, along with side effects of PTX including peripheral neuropathy or hypersensitivity associated with the vehicle used to overcome its poor solubility, are responsible for intensive research concerning the use of PTX in preclinical and clinical studies. Novelties such as albumin-bound PTX (nab-PTX) demonstrate a progressive approach leading to higher efficiency and decreased risk of side effects after drug administration. Moreover, PTX nanoparticles for targeted treatment of BC promise a stable and efficient therapeutic intervention. Here, we summarize current research focused on PTX, its evaluations in preclinical research and application clinical practice as well as the perspective of the drug for future implication in BC therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Taxol and Taxane Production by Taxomyces andreanae , an Endophytic Fungus of Pacific Yew
Stierle, A., Strobel, G., & Stierle, D. (1993) · Science · doi:10.1126/science.8097061 · Cited by 1,701
ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics
McPherson, K. (2000) · BMJ · doi:10.1136/bmj.321.7261.624 · Cited by 1,570
How Taxol/paclitaxel kills cancer cells
Weaver, B. A. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0916 · Cited by 1,547
Choosing the right cell line for breast cancer research
Holliday, D. L., & Speirs, V. (2011) · Breast Cancer Research · doi:10.1186/bcr2889 · Cited by 1,541
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C. F., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9212 · Cited by 1,402
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Biological subtypes of breast cancer: Prognostic and therapeutic implications
Yersal, O. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.412 · Cited by 1,156
Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping
Dai, X., Cheng, H., Bai, Z., & Li, J. (2017) · Journal of Cancer · doi:10.7150/jca.18457 · Cited by 1,100
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.
Jordan, M. A., Toso, R. J., Thrower, D., & Wilson, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9552 · Cited by 1,095
Taxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Kao, J., Salari, K., Bocanegra, M., Choi, Y.-L., Girard, L., Gandhi, J., Kwei, K. A., Hernandez-Boussard, T., Wang, P., Gazdar, A. F., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006146 · Cited by 788
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Mamounas, E. P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S. M., Fisher, B., Wickerham, D. L., Yothers, G., Soran, A., & Wolmark, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.517 · Cited by 714
Doxorubicin, DNA torsion, and chromatin dynamics
Yang, F., Teves, S. S., Kemp, C. J., & Henikoff, S. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.002 · Cited by 695
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.
Haldar, S., Chintapalli, J., & Croce, C. M. (1996) · PubMed · Cited by 651
Microtubules and actin filaments: dynamic targets for cancer chemotherapy
Jordan, M. A., & Wilson, L. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80095-1 · Cited by 614
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
Bcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy
Flatters, S. J. L., & Bennett, G. J. (2004) · Pain · doi:10.1016/j.pain.2004.01.029 · Cited by 576
Gene expression profiling of breast cell lines identifies potential new basal markers
Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adélaïde, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., Birnbaum, D., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209254 · Cited by 569
Tumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 561
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
First total synthesis of taxol. 2. Completion of the C and D rings
Holton, R. A., Kim, H. B., Somoza, C., Liang, F., Biediger, R. J., Boatman, P. D., Shindo, M., Smith, C. C., & Kim, S. (1994) · Journal of the American Chemical Society · doi:10.1021/ja00083a067 · Cited by 524
Paclitaxel: a review of adverse toxicities and novel delivery strategies
Marupudi, N. I., Han, J. E., Li, K. W., Renard, V. M., Tyler, B. M., & Brem, H. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.5.609 · Cited by 510
Kops, G. J. P. L., Foltz, D. R., & Cleveland, D. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401142101 · Cited by 437
Wanderley, C. W., Colón, D. F., Luiz, J. P. M., Oliveira, F. F., Viacava, P. R., Leite, C. A., Pereira, J. A., Silva, C. M., Silva, C. R., Silva, R. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3480 · Cited by 420
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
Rouzier, R., Rajan, R., Wagner, P., Hess, K. R., Gold, D. L., Stec, J., Ayers, M., Ross, J. S., Zhang, P., Buchholz, T. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408974102 · Cited by 413
Breast Cancer: Magnitude of the Problem and Descriptive Epidemiology
Kelsey, J. L., & Horn-Ross, P. L. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036118 · Cited by 400
Recent Advances in the Treatment of Breast Cancer
Tong, C. W. S., Wu, M., Cho, W. C. S., & To, K. K. W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00227 · Cited by 399
Desai, N., Trieu, V., Damascelli, B., & Soon-Shiong, P. (2009) · Translational Oncology · doi:10.1593/tlo.09109 · Cited by 396
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
De Brabander, M., Geuens, G., Nuydens, R., Willebrords, R., & De Mey, J. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5608 · Cited by 387
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.
Blagosklonny, M. V., Giannakakou, P., El‐Deiry, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L. M., & Fojo, T. (1997) · PubMed · Cited by 382
Seidman, A. D., Hudis, C. A., Albanell, J., Albanel, J., Tong, W., Tepler, I., Currie, V, Moynahan, M. E., Theodoulou, M., Gollub, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3353 · Cited by 378
Molecular effects of paclitaxel: Myths and reality (a critical review)
Blagosklonny, M. V., & Fojo, T. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991008)83:2<151::aid-ijc1>3.0.co;2-5 · Cited by 363
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
Möbus, V. (2016) · Breast Care · doi:10.1159/000444004 · Cited by 354
Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T. J., & Hung, M.-C. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80157-4 · Cited by 353
Introduction to Cancer Chemotherapeutics
Shewach, D. S., & Kuchta, R. D. (2009) · Chemical Reviews · doi:10.1021/cr900208x · Cited by 323
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
Shimelis, H., LaDuca, H., Hu, C., Hart, S. N., Na, J., Thomas, A., Akinhanmi, M., Moore, R. M., Brauch, H., Cox, A., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy106 · Cited by 305
Burstein, H. J., Harris, L. N., Gelman, R., Lester, S. C., Nunes, R. A., Kaelin, C. M., Parker, L. M., Ellisen, L. W., Kuter, I., Gadd, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.124 · Cited by 280
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
Goodspeed, A., Heiser, L. M., Gray, J. W., & Costello, J. C. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0189 · Cited by 276
Winer, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270
Ibrahim, N. K., Samuels, B., Page, R., Doval, D., Patel, K. M., Rao, S. C., Nair, M. K., Bhar, P., Desai, N., & Hortobagyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267
Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint
Sudo, T., Nitta, M., Saya, H., & Ueno, N. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2013 · Cited by 262
Direct effect of Taxol on free radical formation and mitochondrial permeability transition
Varbiro, G., Veres, B., Gallyas, F., & Sumegi, B. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00616-5 · Cited by 251
Reichman, B. S., Seidman, A. D., Crown, J. P., Heelan, R., Hakes, T. B., Lebwohl, D. E., Gilewski, T. A., Surbone, A., Currie, V, & Hudis, C. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1943 · Cited by 237
Khongkow, P., Gomes, A. R., Gong, C., Man, E. P. S., Tsang, J. W.-H., Zhao, F., Monteiro, L. J., Coombes, R. C., Medema, R. H., Khoo, U. S., et al. (2016) · Oncogene · doi:10.1038/onc.2015.152 · Cited by 233
Giannakakou, P., Robey, R., Fojo, T., & Blagosklonny, M. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204487 · Cited by 229
Riaz, M., van Jaarsveld, M. T., Hollestelle, A., Prager-van der Smissen, W. J., Heine, A. A., Boersma, A. W., Liu, J., Helmijr, J., Ozturk, B., Smid, M., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3415 · Cited by 218
Long, B. H., & Fairchild, C. R. (1994) · PubMed · Cited by 209
Kidd, J. F., Pilkington, M. F., Schell, M. J., Fogarty, K. E., Skepper, J. N., Taylor, C. W., & Thorn, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106802200 · Cited by 205
Antimitotic drugs in the treatment of cancer
van Vuuren, R. J., Visagie, M. H., Theron, A. E., & Joubert, A. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2903-8 · Cited by 200
Donaldson, K. L., Goolsby, G. L., & Wahl, A. F. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570614 · Cited by 192
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Abotaleb, M., Kubatka, P., Caprnda, M., Varghese, E., Zolakova, B., Zubor, P., Opatrilova, R., Kruzliak, P., Stefanicka, P., & Büsselberg, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.108 · Cited by 184
Self-citationTaxol induction of p21WAF1 and p53 requires c-raf-1.
Blagosklonny, M. V., Schulte, T. W., Nguyen, P., Mimnaugh, E. G., Trepel, J. B., & Neckers, L. M. (1995) · PubMed · Cited by 182
Leveraging the Activity of Tumor Vaccines with Cytotoxic Chemotherapy
Emens, L. A., & Jaffee, E. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1797 · Cited by 182
Claudin-Low Breast Cancer; Clinical & Pathological Characteristics
Dias, K., Dvorkin-Gheva, A., Hallett, R. M., Wu, Y., Hassell, J., Pond, G. R., Levine, M., Whelan, T., & Bane, A. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0168669 · Cited by 178
Blood-based DNA methylation as biomarker for breast cancer: a systematic review
Tang, Q., Cheng, J., Cao, X., Surowy, H., & Burwinkel, B. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0282-6 · Cited by 177
Endocrine Therapy of Breast Cancer
Lumachi, F., Luisetto, G., M.M. Basso, S., Basso, U., Brunello, A., & Camozzi, V. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794480177 · Cited by 176
Blum, J. L., Savin, M. A., Edelman, G., Pippen, J. E., Robert, N. J., Geister, B. V., Kirby, R. L., Clawson, A., & O'Shaughnessy, J. A. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.049 · Cited by 172
Javeed, A., Ashraf, M., Riaz, A., Ghafoor, A., Afzal, S., & Mukhtar, M. M. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.08.009 · Cited by 172
Bristow, M. R., Sageman, W. S., Scott, R. H., Billingham, M. E., Bowden, R. E., Kernoff, R. S., Snidow, G. H., & Daniels, J. R. (1980) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-198009000-00002 · Cited by 171
Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells
Chowdhury, P., Nagesh, P. K. B., Hatami, E., Wagh, S., Dan, N., Tripathi, M. K., Khan, S., Hafeez, B. B., Meibohm, B., Chauhan, S. C., et al. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.09.072 · Cited by 162
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Baselga, J. M., Seidman, A. D., Rosen, P. P., & Norton, L. (1997) · PubMed · Cited by 157
Gianni, L., Mansutti, M., Antón, A., Calvo, L., Bisagni, G., Bermejo, B., Семиглазов, В. Ф., Thill, M., Chacón, J. I., Chan, A., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4612 · Cited by 156
Paclitaxel: new uses for an old drug
Dong, Z., Zhang, D., Yang, R., & Wang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s56801 · Cited by 149
Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Vahdat, L. T., Papadopoulos, K. P., Lange, D., Leuin, S. C., Kaufman, E. A., Donovan, D., Frederick, D., Bagiella, E., Tiersten, A., NICHOLS, G. L., et al. (2001) · PubMed · Cited by 149
Roy, V., LaPlant, B. R., Gross, G. G., Bane, C. L., & Palmieri, F. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn661 · Cited by 145
Integration of phytochemicals and phytotherapy into cancer precision medicine
Efferth, T., Saeed, M. E. M., Mirghani, E., Alim, A., Yassin, Z., Saeed, E. M., Khalid, H. E., & Daak, S. (2017) · Oncotarget · doi:10.18632/oncotarget.17466 · Cited by 143
The MDR superfamily of genes and its biological implications.
Childs, S. J., & Ling (1994) · PubMed · Cited by 139
Ofir, R., Seidman, R., Rabinski, T., Krup, M., Yavelsky, V., Weinstein, Y., & Wolfson, M. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401012 · Cited by 129
Vinothini, K., Rajendran, N. K., Ramu, A., Elumalai, N., & Rajan, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.008 · Cited by 126
Němcová‐Fürstová, V., Kopperová, D., Balušíková, K., Ehrlichová, M., Brynychová, V., Václavíková, R., Daniel, P., Souček, P., & Kovár̆, J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.020 · Cited by 121
Role of microRNAs in chemoresistance.
Magee, P., Shi, L., & Garofalo, M. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.11.32 · Cited by 119
Narayanan, S., Mony, U., Vijaykumar, D. K., Koyakutty, M., Paul‐Prasanth, B., & Menon, D. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.03.015 · Cited by 112
Baek, J.-S., & Cho, C. (2017) · Oncotarget · doi:10.18632/oncotarget.16153 · Cited by 108
Ayoub, N. M., Al-Shami, K. M., & Yaghan, R. J. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s175360 · Cited by 100
The Role of MicroRNAs in Chemoresistance
Bahreini, F., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_336-1 · Cited by 100
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
Yamamoto, Y., Kawano, I., & Iwase (2011) · OncoTargets and Therapy · doi:10.2147/ott.s13836 · Cited by 99
Risk factors for distant metastasis of patients with primary triple-negative breast cancer
Yao, Y., Chu, Y., Xu, B., Hu, Q., & Song, Q. (2019) · Bioscience Reports · doi:10.1042/bsr20190288 · Cited by 99
From taxol to taxol®: The changing identities and ownership of an anti-cancer drug
Walsh, V., & Goodman, J. (2002) · Medical Anthropology · doi:10.1080/01459740214074 · Cited by 93
Shetti, D., Zhang, B., Fan, C., Mo, C., Lee, B. H., & Wei, K. (2019) · Cells · doi:10.3390/cells8080892 · Cited by 85
A Multistep Model for Paclitaxel-Induced Apoptosis in Human Breast Cancer Cell Lines
Blajeski, A. L., Kottke, T. J., & Kaufmann, S. H. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5349 · Cited by 84
Safety and Efficacy of nab -Paclitaxel in the Treatment of Patients with Breast Cancer
Vishnu, P., & Roy, V. (2011) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s5857 · Cited by 83
Walsh, V., & Goodman, J. (1999) · Social Science & Medicine · doi:10.1016/s0277-9536(99)00161-6 · Cited by 78
Wang, H. H., Vo, T. M., Hajar, A., Li, S., Chen, X., Parissenti, A. M., Brindley, D. N., & Wang, Z. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-37 · Cited by 78
Protein Kinase Targets in Breast Cancer
García‐Aranda, M., & Redondo, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122543 · Cited by 78
Differential effects of Paclitaxel on dendritic cell function
John, J., Ismail, M., Riley, C. L., Askham, J. M., Morgan, R., Melcher, A. A., & Pandha, H. (2010) · BMC Immunology · doi:10.1186/1471-2172-11-14 · Cited by 74
Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review
Jasra, S., & Anampa, J. D. S. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0547-8 · Cited by 74
Duan, T., Xu, Z., Sun, F., Wang, Y., Zhang, J., Luo, C., & Wang, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109121 · Cited by 74
Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells
Lv, K., Liu, L., Wang, L., Yu, J., Liu, X., Cheng, Y., Dong, M., Teng, R., Wu, L., Fu, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040008 · Cited by 72
Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers
Montana, M., Castera‐Ducros, C., Verhaeghe, P., Terme, T., Vanelle, P., & Rathelot, P. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.2.59 · Cited by 72
Temperature-dependent reversible assembly of taxol-treated microtubules.
Collins, C. A., & Vallee, R. B. (1987) · The Journal of Cell Biology · doi:10.1083/jcb.105.6.2847 · Cited by 67
Zhu, A., Yuan, P., Du, F., Hong, R., Ding, X., Shi, X., Fan, Y., Wang, J., Luo, Y., Ma, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10532 · Cited by 66
Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer
Yang, N., Wang, C., Wang, J., Wang, Z., Huang, D., Yan, M., Muhammad, K. I., Liu, Q., & Xu, B. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14538 · Cited by 66
Pan, Z. Z., Avila, A., & Gollahon, L. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15022672 · Cited by 63
Xu, R., Sato, N., Yanai, K., Akiyoshi, T., Nagai, S., 和田, 純., Koga, K., Mibu, R., Nakamura, M., & Katano, M. (2009) · PubMed · Cited by 62
Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption
Wang, Y., Zhou, Y., Zheng, Z., Li, J., Yan, Y., & Wu, W. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1174-9 · Cited by 57
Shetty, N., & Gupta, S. (2014) · South Asian Journal of Cancer · doi:10.4103/2278-330x.126527 · Cited by 56
CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50
Chi, Y., Xue, J., Huang, S., Xiu, B., Su, Y., Wang, W., Guo, R., Wang, L., Li, L., Shao, Z., et al. (2019) · Theranostics · doi:10.7150/thno.36338 · Cited by 56
The role of dietary phytochemicals in the carcinogenesis via the modulation of miRNA expression
Samec, M., Líšková, A., Kubatka, P., Uramova, S., Žúbor, P., Samuel, S. M., Zulli, A., Péč, M. J., Bielik, T., Biringer, K., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02940-0 · Cited by 52
Self-citationZhang, Q., Zhao, J., Hu, H., Yan, Y., Hu, X., Zhou, K., Xiao, S., Zhang, Y., & Feng, N. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118595 · Cited by 50
Clătici, V. G., Voicu, C., Voaideṣ, C., Roșeanu, A., Icriverzi, M., & Jurcoane, Ș. (2018) · Europe PMC (PubMed Central) · doi:10.26574/maedica.2018.13.4.273 · Cited by 50
Triple negative breast cancer: new therapeutic approaches and BRCA status
Eskiler, G. G., Çeçener, G., Egelí, Ü., & Tunca, B. (2018) · Apmis · doi:10.1111/apm.12836 · Cited by 49
Çetin, İ., & Topçul, M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.6.2427 · Cited by 47
Jabri, T., Imran, M., Aziz, A., Rao, K., Kawish, M., Irfan, M., Malik, M. I., Sımjee, S. U., Arfan, M., & Shah, M. R. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1550091 · Cited by 47
Cytokines as Mediators of Pain‐Related Process in Breast Cancer
Panis, C., & Pavanelli, W. R. (2015) · Mediators of Inflammation · doi:10.1155/2015/129034 · Cited by 46
Iglesias, J. (2009) · Breast Cancer Research · doi:10.1186/bcr2282 · Cited by 44
Megerdichian, C., Olimpiadi, Y. B., & Hurvitz, S. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.02.001 · Cited by 43
Lasham, A., Mehta, S. Y., Fitzgerald, S. J., Woolley, A. G., Hearn, J. I., Hurley, D., Ruza, I., Algie, M., Shelling, A. N., Braithwaite, A. W., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30137 · Cited by 41
Taxane benefit in breast cancer—a role for grade and chromosomal stability
A’Hern, R., Jamal‐Hanjani, M., Szász, A. M., Johnston, S. R. D., Reis-Filho, J. S., Roylance, R. R., & Swanton, C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.67 · Cited by 39
Kubo, M., Morisaki, T., Matsumoto, K., Tasaki, A., Yamanaka, N., Nakashima, H., Kuroki, H., Nakamura, K., Nakamura, M., & Katano, M. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0617-6 · Cited by 39
Genetics of triple-negative breast cancer: Implications for patient care
Afghahi, A., Telli, M. L., & Kurian, A. W. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.007 · Cited by 38
Shen, F., Long, D., Yu, T., Chen, X., Liao, Y., Wu, Y., & Lin, X. (2017) · Oncology Reports · doi:10.3892/or.2017.5469 · Cited by 38
Mahtani, R. L., Parisi, M., Glück, S., Ni, Q., Park, S., Pelletier, C. L., Faria, C., & Braiteh, F. (2018) · Cancer Management and Research · doi:10.2147/cmar.s150960 · Cited by 36
Žúbor, P., Kubatka, P., Daňková, Z., Gondova, A., Kajo, K., Hatok, J., Samec, M., Jagelková, M., Krivus, S., Holubeková, V., et al. (2018) · Future Oncology · doi:10.2217/fon-2018-0061 · Cited by 36
Self-citationMonteiro, L. O. F., Fernandes, R. S., Castro, L. C., dos Reis, D. C., Cassali, G. D., Evangelista, F. C. G., Loures, C. M. C., Sabino, A. D. P., Cardoso, V. N., Oliveira, M. C., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00329 · Cited by 36
Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness
Tran, T.-A., Gillet, L., Roger, S., Besson, P., White, E., & Guennec, J. L. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.073 · Cited by 34
Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer
Kim, S., Jung, W. H., & Koo, J. S. (2012) · Tumor Biology · doi:10.1007/s13277-012-0424-1 · Cited by 29
Widodo, I., Dwianingsih, E. K., Anwar, S. L., Ediati, T. F., Utoro, T., Aryandono, T., & Soeripto (2017) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2017.18.5.1251 · Cited by 28
Hoffman, R. M., & Bouvet, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1016912 · Cited by 27
SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells
de Moraes, G. N., Ji, Z., Fan, L. Y.-N., Yao, S. J., Zona, S., Sharrocks, A. D., & Lam, E. W. ‐. (2018) · Oncogenesis · doi:10.1038/s41389-018-0038-6 · Cited by 27
Phytochemicals Formulated As Nanoparticles: Inventions, Recent Patents and Future Prospects
Jadhav, N. R., Nadaf, D. S., Lohar, D. A., Ghagare, P., & Powar, T. A. (2017) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/1872211311666171120102531 · Cited by 24
Martín, M., Chacón, J. I., Antón, A., Plazaola, A., García-Martínez, E., Seguí, M. Á., Sánchez‐Rovira, P., Palacios, J., Calvo, L., Esteban, C., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0052 · Cited by 22
Asghari, F., Haghnavaz, N., Shanehbandi, D., Khaze, V., Baradaran, B., & Kazemi, T. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/70745 · Cited by 22
Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy
Shin, D. H., & Kwon, G. S. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.01.006 · Cited by 19
Zhang, L., Wu, C., Mu, S., Xue, W., & Ma, D. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.06.052 · Cited by 19
Emami, J., Rezazadeh, M., Mashayekhi, M., Rostami, M. R., & Jahanian‐Najafabadi, A. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1411940 · Cited by 18
Taxanes in the elderly patient with metastatic breast cancer
Yardley, D. A. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s87638 · Cited by 15
Takashima, T., Kawajiri, H., Nishimori, T., Tei, S., Nishimura, S., Yamagata, S., Tokunaga, S., Mizuyama, Y., Sunami, T., Tezuka, K., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12233 · Cited by 13
Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
Si, W., Zhu, Y., Li, Y., Gao, P., Han, C., You, J., Linghu, R., Jiao, S., & Yang, J. L. (2013) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20133168 · Cited by 7
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 406
Computer especially AI-assisted drug virtual screening and design in traditional Chinese medicine
Lin, Y., Zhang, Y., Wang, D., Yang, B., & Shen, Y.-Q. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154481 · Cited by 107
Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF‐α pathway
Su, S., Dou, H., Wang, Z., & Zhang, Q. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13487 · Cited by 32
Zhuang, Y., Grainger, J. M., Vedell, P. T., Yu, J., Moyer, A. M., Gao, H., Fan, X.-Y., Qin, S., Liu, D., Kalari, K. R., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00285-x · Cited by 11
Metadata
- Authors
- Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2019-11-27
- Volume
- 9
- Issue
- 12
- Pages
- 789
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W2991274658
- Cited by
- 569
- References
- 143
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.